Usmani Highlights the Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

0 Lượt xem· 09/04/23
OncLive® On Air
OncLive® On Air
0 Người đăng ký
0
Trong

Dr Usmani discusses the integration of elranatamab, talquetamab, and telcistamab into the management of relapsed/refractory multiple myeloma, common adverse effects and recommended supportive care measures, and ongoing research that may help clarify their role in the paradigm.

Cho xem nhiều hơn

 0 Bình luận sort   Sắp xếp theo


Tiếp theo